PharmaJet and Diomics Partner on SARS-CoV-2 Immune Response Monitoring

November 18, 2020

The Baytown Sun

GOLDEN, Colo.–(BUSINESS WIRE)–Nov 17, 2020–

PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Tropis ® Needle-free Injection System will be used by Diomics, a San Diego-based biotech company, to deliver a biopolymer to detect the formation of an immune response to a SARS-CoV-2 protein. The company was awarded over $2 million by the Department of Defense to accelerate testing of its Diocheck™ system and is expected to begin human clinical trials in December 2020… Read more…